These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19255112)

  • 1. The evolution of influenza resistance and treatment.
    Weinstock DM; Zuccotti G
    JAMA; 2009 Mar; 301(10):1066-9. PubMed ID: 19255112
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug resistance. A 'wimpy' flu strain mysteriously turns scary.
    Enserink M
    Science; 2009 Feb; 323(5918):1162-3. PubMed ID: 19251605
    [No Abstract]   [Full Text] [Related]  

  • 3. Implications of antiviral resistance of influenza viruses.
    Monto AS
    Clin Infect Dis; 2009 Feb; 48(4):397-9. PubMed ID: 19586376
    [No Abstract]   [Full Text] [Related]  

  • 4. Surveillance for antiviral resistance.
    Zambon MC
    Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):37-43. PubMed ID: 23279895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.
    Baz M; Abed Y; Papenburg J; Bouhy X; Hamelin ME; Boivin G
    N Engl J Med; 2009 Dec; 361(23):2296-7. PubMed ID: 19907034
    [No Abstract]   [Full Text] [Related]  

  • 6. Global transmission of oseltamivir-resistant influenza.
    Moscona A
    N Engl J Med; 2009 Mar; 360(10):953-6. PubMed ID: 19258250
    [No Abstract]   [Full Text] [Related]  

  • 7. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa.
    Besselaar TG; Naidoo D; Buys A; Gregory V; McAnerney J; Manamela JM; Blumberg L; Schoub BD
    Emerg Infect Dis; 2008 Nov; 14(11):1809-10. PubMed ID: 18976580
    [No Abstract]   [Full Text] [Related]  

  • 8. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
    Perez-Sautu U; Pozo F; Cuesta I; Monzon S; Calderon A; Gonzalez M; Molinero M; Lopez-Miragaya I; Rey S; Cañizares A; Rodriguez G; Gonzalez-Velasco C; Lackenby A; Casas I
    Euro Surveill; 2014 Jul; 19(27):14-20. PubMed ID: 25033052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1).
    Uyeki T
    N Engl J Med; 2009 Dec; 361(23):e110. PubMed ID: 19923564
    [No Abstract]   [Full Text] [Related]  

  • 10. [Drug-resistant influenza viruses: an overview].
    Hatakeyama S
    Nihon Rinsho; 2010 Sep; 68(9):1671-8. PubMed ID: 20845746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oseltamivir resistance: what does it mean clinically?
    Baum SG
    Clin Infect Dis; 2009 Dec; 49(12):1836-7. PubMed ID: 19911972
    [No Abstract]   [Full Text] [Related]  

  • 12. Pandemic influenza: an inconvenient mutation.
    Layne SP; Monto AS; Taubenberger JK
    Science; 2009 Mar; 323(5921):1560-1. PubMed ID: 19299601
    [No Abstract]   [Full Text] [Related]  

  • 13. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
    Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
    Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virology. Helping the resistance.
    Holmes EC
    Science; 2010 Jun; 328(5983):1243-4. PubMed ID: 20522766
    [No Abstract]   [Full Text] [Related]  

  • 15. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
    Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
    Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
    Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.
    van der Vries E; Stelma FF; Boucher CA
    N Engl J Med; 2010 Sep; 363(14):1381-2. PubMed ID: 20879894
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
    Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV
    J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GFP-expressing influenza A virus for evaluation of the efficacy of antiviral agents.
    Kim JI; Park S; Lee I; Lee S; Shin S; Won Y; Hwang MW; Bae JY; Heo J; Hyun HE; Jun H; Lim SS; Park MS
    J Microbiol; 2012 Apr; 50(2):359-62. PubMed ID: 22538668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.